• Boards to assist in demonstrating added value of using PharmaJet’s delivery technology to improve performance of vaccines and therapeutics.
• The Scientific Advisory Boards bring together renowned industry experts in infectious diseases and oncology to accelerate PharmaJet’s partnering strategy with vaccine and pharmaceutical companies.
• Presentation scheduled for April 1, 2024 at 2:00 PM ET in Room 202A at the Walter E. Washington Convention Center, Washington, D.C.

PharmaJet^®, a company that strives to improve the performance and outcomes of medicines with its innovative delivery systems, today announced the formation of two Scientific Advisory Boards (SAB) comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping. The Boards will provide strategic guidance and expertise to help PharmaJet advance its vision to better activate the immune system with its unique technology and accelerate its partnering strategy with vaccine and pharmaceutical companies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401778401/en/

In the countries highlighted, PharmaJet has commercial and development partners for prophylactic vaccines for the prevention of infectious diseases as well as cancer treatments. (Graphic: Business Wire)

“The formation of our SABs is a significant step forward in our mission to demonstrate how our delivery technology can improve the performance of vaccines and therapeutics,” said Chris Cappello, President, and Chief Executive Officer, PharmaJet. “We are pleased to assemble such a distinguished group of advisors and look forward to their deep insights as leading experts in the infectious diseases and oncology fields. Their valuable guidance will inform the clinical and commercial advancement of our innovative delivery technology, aligning our priorities with prospective partners and global health needs.”

The PharmaJet Tropis^® (for intradermal administration) and Stratis^® (for intramuscular and subcutaneous administration) are the only commercially scaled needle-free technologies that enhance the performance of several vaccines and therapeutics. To date, more than 10 million vaccinations have been made and PharmaJet has over 80 global development partners.

The new PharmaJet Scientific Advisory Boards include the esteemed industry experts below:

• Infectious Diseases
  • Cornelia Dekker, M.D., Professor of Pediatrics (Infectious Diseases), Emerita, Stanford University School of Medicine; former Vice President, Clinical Research and Medical Affairs, Chiron Vaccines
  • James Merson, Ph.D.*, Chief Virology Officer, stealth Oncology company; former SVP and CSO, Vaccine Immunotherapeutics Research Unit, Pfizer
  • Jonathan Nguyen-Van-Tam, independent consultant, former Medical Director, Sanofi Pasteur MSD and Former Deputy Chief Medical Officer, UK Government
  • Bali Pulendran, Ph.D., Co-Director, Institute for Immunity, Transplantation and Infection, Stanford University, and Violetta L. Horton Professor of Pathology, and of Microbiology and Immunology
  • Brian Ward, MDCM, Professor of Infectious Diseases/Microbiology, McGill University; former Medical Officer, Medicago Inc.

• Oncology
  • Michael Gibson, M.D., Ph.D., FACP, Director, Translational Research for Esophago-Gastric Cancer (EGC) at the Vanderbilt-Ingram Cancer Center (VICC)
  • Stephanie Mazzei, MSc, Founder and Director, OncoLogic Inc.; global oncology Strategic Advisor
  • Douglas McNeel, M.D., Ph.D., Professor of Medicine, Director, Solid Tumor Immunology Research, Co-Director, University of Wisconsin Prostate SPORE, UW Carbone Cancer Center
  • James Merson, Ph.D.*, see above.
  • Patrick Ott, M.D., Ph.D., Clinical Director, Melanoma Center, Dana Farber Cancer Institute

*James Merson is a member of both SABs

Full bios of the Scientific Advisory Boards are available on the PharmaJet website.

PharmaJet will be participating at the World Vaccine Congress April 1-4, 2024, in Washington, D.C. In addition to exhibiting at the event, Nathalie Landry, Chief Scientific Officer, PharmaJet will present Improving the performance of vaccines with precision-delivery technologies at a Vaccine Delivery Workshop on April 1 beginning at 2:00 pm ET in Room 202A. To find out how this innovative technology can help your vaccine or therapeutic program, schedule a meeting with one of our company experts by clicking here.

For more information about PharmaJet visit https://pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

About PharmaJet

The PharmaJet mission is to improve the performance and outcomes of medicines with our innovative delivery systems that better activate the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis^® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis^® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information visit https://pharmajet.com. Follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240401778401/en/